UCB Sa operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares UCB Sa with three other
pharmaceutical manufacturers in Europe:
H. Lundbeck A/S
of Denmark
(2017
sales of 17.23 billion Danish Kroner [US$2.84 billion]
of which 18%
was Onfi),
Protek PAO
of Russia
(258.45 billion Russian Rubles [US$4.21 billion]
of which 78%
was Distribution), and
Lonza Group AG
which is
based in Switzerland
(5.11 billion Swiss Francs [US$5.24 billion]
of which 47%
was Specialty Ingredients).
Sales Analysis.
UCB Sa reported sales of 4.53 billion Euro (US$5.57 billion)
for the
year ending
December of 2017.
This
represents
an
increase of 8.4%
versus 2016, when the company's sales were 4.18 billion Euro.
This was the third consecutive year of growth at UCB Sa.